Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

727.20 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,001
Open 727.20
Bid (Size) 720.00 (4)
Ask (Size) 723.00 (1)
Prev. Close 727.20
Today's Range 727.20 - 727.20
52wk Range 561.65 - 972.53
Shares Outstanding N/A
Dividend Yield 0.62%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Smartest Megacap Growth ETF to Buy With $500 Right Now
Via The Motley Fool
Topics ETFs
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
Eli Lilly's Phase 3 SUMMIT trial results show tirzepatide's potential to reduce heart failure risk and improve symptoms in obese adults with HFpEF. 
Via Benzinga

Performance

YTD
+22.80%
+22.80%
1 Month
-19.75%
-19.75%
3 Month
-21.11%
-21.11%
6 Month
-7.15%
-7.15%
1 Year
+21.69%
+21.69%

More News

Read More
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now
Via The Motley Fool
Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth
Via Benzinga
Topics Economy
Exposures Economy
Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Years From Now
Via The Motley Fool
Eli Lilly Unusual Options Activity For November 13
Via Benzinga
Not-So-Big Pharma
Via Talk Markets
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Via The Motley Fool
Topics Government
Exposures Political
AskSlim Market Week - Friday, Nov. 15
Via Talk Markets
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
Via Benzinga
Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Via The Motley Fool
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Via Benzinga
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
2 Top Growth Stocks to Buy on the Dip
Via The Motley Fool
3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years
Via The Motley Fool
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Via Benzinga
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Via The Motley Fool
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
Via Benzinga
2 S&P 500 Dividend Stocks That Could Soar 30% or More, According to a Pair of Wall Street Analysts
Via The Motley Fool
Topics Stocks
Exposures US Equities
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Via Benzinga
Tradepulse Power Inflow Alert: Eli Lilly & Company Moves Up Over 13 Points After Signal
Via Benzinga
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
Via Investor's Business Daily
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.